This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 100% and 7.93%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
MiMedx (MDXG) delivered earnings and revenue surprises of 40% and 3.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include TAL Education Group (TAL), BioCardia (BCDA), Angi (ANGI), Xcel Energy (XEL) and SoFi Technologies (SOFI).
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
by Zacks Equity Research
The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
by Zacks Equity Research
BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
by Zacks Equity Research
Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -13.33% and 87.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -5.88% and 21.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will High Costs & Low Sales Dent Braskem (BAK) Q1 Earnings?
by Zacks Equity Research
Braskem's (BAK) upward cost trajectory is likely to have continued in the first quarter due to higher feedstock prices in international markets and global supply chain constraints.
Ovintiv (OVV) Q1 Earnings Coming Up: Here's How It Will Fare
by Zacks Equity Research
Ovintiv's (OVV) first-quarter earnings are expected to have benefited from the surge in oil and natural gas prices.
Will Suncor (SU) Reverse the Previous Miss in Q1 Earnings?
by Zacks Equity Research
Suncor Energy (SU) is expected to have benefited from the surge in oil realizations.
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
by Zacks Equity Research
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -109.09% and 11.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?